Ethan B. Russo
Medical Hypotheses · 2006
A researcher in the Science corpus: 1 paper; trusts 0 researchers and is trusted by 1 researcher here, as inferred from the citation graph.
Who trusts Ethan B. Russo overall
Papers from Ethan B. Russo's perspective
Ordered by how strongly the researchers Ethan B. Russo trusts endorse each paper. Same corpus, a different order for every researcher.
- Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide (British Journal of Pharmacology)
- Agonistic Properties of Cannabidiol at 5-HT1a Receptors (Neurochemical Research)
- Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. (The Lancet)
- The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. (Proceedings of the National Academy of Sciences of the United States of America)
- The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1) (British Journal of Pharmacology)
- Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. (Brain Research)
- Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1 (Nature)
- Brain monoglyceride lipase participating in endocannabinoid inactivation (Proceedings of the National Academy of Sciences of the United States of America)
- The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin
- Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain (Journal of Cell Biology)